+ 44 (0) 20 7127 5089

information(at)fulhold.com

Combating the rising tide of multi-resistant superbugs

Mission Statement

Our Mission is to develop and commercialise the worldwide use of CarboHydrate Derived Fulvic Acid (CHD-FA) in Human and Animal Healthcare.

Strategy

Image title

Re-usable evidence such as the proven safety and toxicity data means that CHD-FA can provide the platform technology for a wide range of applications at vastly reduced timeframes and cost.

We plan to launch a range of ‘application’ companies in various sectors with a view to developing these value propositions in order to

  • secure licensing deals for formulated products
  • embark on joint ventures
  • list or sell these entities.

Fulhold is currently seeking U.S. and EU Regulatory approvals for both the active ingredient itself and also formulated products for an initial set of applications such as

  • drug-resistant wound care
  • oral health
  • veterinary uses
  • new products in combination with existing antibiotics to address the growing global resistance to antimicrobial medicines.

Our intention is to seek funding in order to accelerate this plan. The funding would be used, for example, to

  • recruit a full-time executive team with extensive pharmaceutical industry experience
  • formulate and test new products
  • conduct clinical trials
  • secure Regulatory approvals